- Home
- ITRM vs RAPT Comparison
ITRM vs RAPT Comparison
Compare ITRM & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRM
- RAPT
- Stock Information
- Founded
- ITRM 2015
- RAPT 2015
- Country
- ITRM Ireland
- RAPT United States
- Employees
- ITRM N/A
- RAPT N/A
- Industry
- ITRM Biotechnology: Pharmaceutical Preparations
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- ITRM Health Care
- RAPT Health Care
- Exchange
- ITRM Nasdaq
- RAPT Nasdaq
- Market Cap
- ITRM 49.5M
- RAPT 59.1M
- IPO Year
- ITRM 2018
- RAPT 2019
- Fundamental
- Price
- ITRM $1.54
- RAPT $1.20
- Analyst Decision
- ITRM Strong Buy
- RAPT Hold
- Analyst Count
- ITRM 1
- RAPT 10
- Target Price
- ITRM $5.00
- RAPT $6.00
- AVG Volume (30 Days)
- ITRM 671.4K
- RAPT 9.1M
- Earning Date
- ITRM 11-14-2024
- RAPT 03-06-2025
- Dividend Yield
- ITRM N/A
- RAPT N/A
- EPS Growth
- ITRM N/A
- RAPT N/A
- EPS
- ITRM N/A
- RAPT N/A
- Revenue
- ITRM N/A
- RAPT N/A
- Revenue This Year
- ITRM N/A
- RAPT N/A
- Revenue Next Year
- ITRM N/A
- RAPT N/A
- P/E Ratio
- ITRM N/A
- RAPT N/A
- Revenue Growth
- ITRM N/A
- RAPT N/A
- 52 Week Low
- ITRM $0.81
- RAPT $0.79
- 52 Week High
- ITRM $3.02
- RAPT $27.35
- Technical
- Relative Strength Index (RSI)
- ITRM 39.39
- RAPT 43.92
- Support Level
- ITRM $1.58
- RAPT $1.07
- Resistance Level
- ITRM $2.10
- RAPT $1.29
- Average True Range (ATR)
- ITRM 0.14
- RAPT 0.17
- MACD
- ITRM -0.04
- RAPT -0.04
- Stochastic Oscillator
- ITRM 11.11
- RAPT 15.43
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.